1,396 results match your criteria Clinical Genitourinary Cancer [Journal]


PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.

Clin Genitourin Cancer 2019 Mar 29. Epub 2019 Mar 29.

New York University Perlmutter Cancer Center, New York, NY.

Chemotherapy is no longer the only viable option for patients with locally advanced or metastatic urothelial carcinoma. Immunotherapy, as checkpoint inhibition, has received United States Food and Drug Administration approval in the preceding several years, both in the second-line and first-line for cisplatin-ineligible patients. Those who respond often do so durably; however, response rates in the first line are 23% to 24%, and are lower in the second line. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.03.009DOI Listing

Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma.

Clin Genitourin Cancer 2019 Mar 29. Epub 2019 Mar 29.

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM) and Institut du Cancer de Montréal, Montréal, Québec, Canada.

Background: Few data examined the potential survival benefit of nephroureterectomy (NU) in the setting of metastatic upper urinary tract urothelial carcinoma (mUTUC). We hypothesized that a survival benefit might be associated with the use of NU in that setting and tested this hypothesis within a large population-based cohort.

Patients And Methods: Within the Surveillance, Epidemiology, and End Results database (2004-2014), we identified 1174 patients with mUTUC. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673193008
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2019.03.003DOI Listing
March 2019
1 Read

Who Can Avoid Systematic Biopsy Without Missing Clinically Significant Prostate Cancer in Men Who Undergo Magnetic Resonance Imaging-Targeted Biopsy?

Clin Genitourin Cancer 2019 Mar 27. Epub 2019 Mar 27.

Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. Electronic address:

Background: The objective of the study was to identify a subset of men who can avoid systematic multisite biopsy (SyB) among those undergoing magnetic resonance imaging (MRI)-targeted transperineal 4-core biopsy (TgB) without missing clinically significant cancer (SC).

Patients And Methods: From April 2013 to December 2017, 304 men with elevated prostate-specific antigen levels (< 20 ng/mL) or abnormal digital rectal examination and positive MRI findings underwent transrecta ultrasound and MRI-targeted transperineal 4-core with 14-core systematic biopsy. MRI findings were prospectively collected and evaluated using Prostate Imaging-Reporting and Data System version 2 (PI-RADS), and scores ≥3 were considered positive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.03.011DOI Listing

Low Rate of Cancer Events After Partial Nephrectomy for Renal Cell Carcinoma: Clinicopathologic Analysis of 1994 Cases with Emphasis on Definition of "Recurrence".

Clin Genitourin Cancer 2019 Mar 23. Epub 2019 Mar 23.

Glickman Urological and Kidney Institute, Department of Urology, Cleveland Clinic, Cleveland, OH. Electronic address:

Background: Systematic pathology reviews in patients who experienced a clinical "recurrence" after partial nephrectomy for renal cell carcinoma (RCC) are anecdotal; therefore, definitions of "recurrence" varies considerably. We aimed to better define local recurrence by re-evaluation of surgical specimens of patients who experienced "recurrences" after partial nephrectomy at our institution.

Materials And Methods: Retrospective analysis of our institutional partial nephrectomy data set was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.03.004DOI Listing

Association Between Hospitals' Risk-Adjusted Emergency Department Visits and Survival and Costs in Kidney Cancer Patients Undergoing Nephrectomy.

Clin Genitourin Cancer 2019 Mar 27. Epub 2019 Mar 27.

Department of Health Policy and Administration, Pennsylvania State University, University Park, PA; Department of Public Health Sciences, Pennsylvania State University, Hershey, PA; Department of Surgery, Penn State College of Medicine, Hershey, PA.

Purpose: To estimate the association between a hospital's risk-adjusted emergency department (ED) visit rate and its risk-adjusted mortality rate and costs among kidney cancer patients undergoing initial nephrectomy.

Patients And Methods: Using 2007-2012 Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we used logistic regression to model ED visit occurrence within 30 and 365 days for all kidney cancer patients receiving initial surgery. Our model controlled for demographics, stage, histology, systemic targeted therapy, and comorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.03.013DOI Listing

Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution.

Clin Genitourin Cancer 2019 Mar 27. Epub 2019 Mar 27.

Northampton General Hospital NHS Trust, Cliftonville, Northampton, United Kingdom.

Background: Elderly metastatic renal cell carcinoma (mRCC) patients are under-represented in clinical trials, whose results are therefore difficult to translate into routine management of older patients. We aimed at exploring treatment outcomes and prognostic factors in our real-life elderly mRCC cohort receiving first-line tyrosine kinase inhibitor (TKI) monotherapy.

Patients And Methods: We retrospectively analyzed demographic and clinicopathological characteristics, and treatment data of elderly (≥ 70 years old at first-line start) mRCC patients starting either pazopanib or sunitinib as first-line treatment in our institution between March 2012 and April 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.03.012DOI Listing

Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.

Clin Genitourin Cancer 2019 Feb 20. Epub 2019 Feb 20.

Clinical Hospital Number 1 of Poznan University of Medical Sciences, Poznan, Poland.

Background: Cabozantinib is an approved treatment for metastatic renal cell carcinoma (mRCC). This report presents an analysis of the safety profile and efficacy of cabozantinib in an unselected population from Poland.

Patients And Methods: Patients with mRCC, who had been treated with at least 1 previous agent targeting the vascular endothelial growth factor pathway, were eligible to receive cabozantinib at a once-daily dose of 60 mg orally, according to the Managed Access Program (MAP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.002DOI Listing
February 2019
1 Read

Incident Chronic Kidney Disease After Radical Nephrectomy for Renal Cell Carcinoma.

Clin Genitourin Cancer 2019 Mar 15. Epub 2019 Mar 15.

QIMR Berghofer Medical Research Institute, Brisbane, Australia; University of Queensland, Brisbane, Australia.

Background: Chronic kidney disease (CKD) after surgery for kidney cancer is common, and is associated with increased morbidity and mortality. This study aimed to identify factors associated with incident CKD in patients managed with radical nephrectomy.

Patients And Methods: All patients diagnosed with renal cell carcinoma between January 2012 and December 2013 were ascertained from state-based cancer registries in Queensland and Victoria. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673193005
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2019.02.011DOI Listing
March 2019
2 Reads

Patterns of Presentation and Treatment Outcomes of Non-clear-cell Renal Cell Carcinoma and Sarcomatoid Renal Cell Carcinoma Patients in 2 Tertiary Referral Centers in Sydney, Australia.

Clin Genitourin Cancer 2019 Feb 27. Epub 2019 Feb 27.

School of Medicine, University of New South Wales, Kensington, New South Wales, Australia; Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia; Western Sydney University, Liverpool, New South Wales, Australia.

Background: Non-clear-cell renal cell carcinoma (nccRCC) and renal cell carcinoma with sarcomatoid features (scRCC) are rare, and represent subtypes with less defined treatment strategies. The aim of this study is to describe the patterns of care and outcomes of these patients in 2 tertiary referral centers in South Western Sydney Local Health District over a 10-year period.

Patients And Methods: Patients with RCC seen at South Western Sydney Local Health District from January 1, 2005 to December 31, 2015 were identified from electronic medical records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.006DOI Listing
February 2019
2 Reads

Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients.

Clin Genitourin Cancer 2019 Feb 28. Epub 2019 Feb 28.

Radiation Oncology Department, La Pitié-Salpêtrière Universitary Hospital, Paris, France.

Background: The objective of the study was to evaluate the outcomes in terms of efficacy and safety of a large consecutive series of 362 patients with renal cell carcinoma (RCC) brain metastases treated using stereotactic radiosurgery (SRS) in the tyrosine kinase inhibitor (TKI) era.

Patients And Methods: From 2005 to 2015, 362 consecutive patients with brain metastases from RCC were treated using SRS in 1 fraction: 226 metastases (61 patients) using Gamma-Knife at a median of 18 Gy (50% isodose line); 136 metastases (63 patients) using linear accelerator at a median of 16 Gy (70% isodose line). The median patient age was 58 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.007DOI Listing
February 2019
1 Read

Synchronous Bilateral RCC Is Associated With Poor Recurrence-Free Survival Compared With Unilateral RCC: A Single-Center Study With Propensity Score Matching Analysis.

Clin Genitourin Cancer 2019 Feb 28. Epub 2019 Feb 28.

Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea. Electronic address:

Background: Understanding the tumorigenesis of bilateral cancers occurring in paired organs is essential for treatment planning and follow-up strategies. To the best of our knowledge, only a few studies compared the survival outcomes in patients with unilateral and bilateral renal cell carcinoma (RCC). We aimed to evaluate the survival outcomes of these patients after surgery and perform a further comparison of synchronous and metachronous bilateral RCCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.008DOI Listing
February 2019
1 Read

Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence.

Clin Genitourin Cancer 2019 Feb 6. Epub 2019 Feb 6.

Department of Urology, Mayo Clinic, Rochester, MN. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.019DOI Listing
February 2019

Angiomyolipoma of the Adrenal Glands.

Clin Genitourin Cancer 2019 Feb 13. Epub 2019 Feb 13.

Department of Diagnostic Radiology, University of Illinois at Chicago, Chicago, IL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.004DOI Listing
February 2019

Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 Feb 5. Epub 2019 Feb 5.

Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Durham, NC. Electronic address:

The incidence of renal-cell carcinoma has been increasing each year, with nearly one third of new cases diagnosed at advanced or metastatic stage. The advent of targeted therapies for metastatic renal-cell carcinoma (mRCC) has underscored the need to subtype tumors according to tumor-immune expression profiles that may more reliably predict treatment outcomes. Over the past 2 decades, several vascular endothelial growth factor (VEGF) and tyrosine kinase inhibitors have been the mainstay for first- and second-line treatment of mRCC. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673193004
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2019.01.017DOI Listing
February 2019
4 Reads

Application of Urinary Volatile Organic Compounds (VOCs) for the Diagnosis of Prostate Cancer.

Clin Genitourin Cancer 2019 Feb 16. Epub 2019 Feb 16.

Department of Chemistry and Biochemistry, University of Texas at El Paso, El Paso, TX. Electronic address:

Background: Prostate cancer (PCa) screening using serum prostate-specific antigen (PSA) testing has caused unnecessary biopsies and overdiagnosis owing to its low accuracy and reliability. Therefore, there is an increased interest in identifying better PCa biomarkers. Studies showed that trained dogs can discriminate patients with PCa from unaffected men by sniffing urine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.003DOI Listing
February 2019
1 Read

A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema.

Clin Genitourin Cancer 2019 Feb 14. Epub 2019 Feb 14.

Genitourinary Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.005DOI Listing
February 2019

Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery.

Clin Genitourin Cancer 2019 Feb 13. Epub 2019 Feb 13.

Unit of Urology/Division of Oncology, IRCCS Ospedale San Raffaele, URI Milan, Milan, Italy.

Introduction: Patients with bladder cancer treated with radical cystectomy (RC) have heterogeneous results in term of cancer-specific (CSM) and other cause mortality (OCM). Our aim is to assess the impact of age on cause of death after RC.

Patients And Methods: We retrospectively analyzed the data of 1222 patients treated with RC and bilateral pelvic lymph node dissection owing to nonmetastatic bladder cancer between 1990 and 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.001DOI Listing
February 2019
1 Read

Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy.

Clin Genitourin Cancer 2019 Jan 29. Epub 2019 Jan 29.

Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

Introduction: Definitive, curatively intended therapy for muscle-invasive bladder cancer can be associated with significant morbidity and adverse effects on quality of life, leaving patients reluctant to opt for these interventions. We sought to provide perspective to patients and clinicians exploring therapy options.

Materials And Methods: We examined stage-by-stage overall survival of definitive therapy (DT) (either radical cystectomy in conjunction with neoadjuvant chemotherapy or trimodal therapy) versus non-DT (including palliative transurethral resection, chemotherapy and radiation treatment) among 42,144 patients within the National Cancer Database (2004-2012). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.009DOI Listing
January 2019

Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.

Clin Genitourin Cancer 2019 Feb 4. Epub 2019 Feb 4.

Service d'Anatomie et Cytologie Pathologiques, Université de Rennes 1, Université Bretagne Loire, Rennes, France; Unité Mixte de Recherche 6290-Institut de Génétique et Développement de Rennes, Rennes, France.

Background: Long-term responders (LTRs) are defined by at least 18 months of response to sunitinib in metastatic clear-cell renal cell carcinoma (ccRCC). Well-described by clinical studies, the phenotype of these tumors has never been explored.

Patients And Methods: In a retrospective and multicenter study, 90 ccRCCs of patients with metastatic disease were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.014DOI Listing
February 2019
6 Reads

Current Therapies of Wilms Tumors in the Adult: Diagnostic Considerations and Treatment Challenges.

Clin Genitourin Cancer 2019 Feb 5. Epub 2019 Feb 5.

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.016DOI Listing
February 2019

New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When.

Clin Genitourin Cancer 2019 Feb 6. Epub 2019 Feb 6.

Breast Cancer Unit and Translational Research Unit, ASST Cremona, Cremona, Italy; Department of Medical, Surgery, and Health Sciences, University of Trieste, Trieste, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.020DOI Listing
February 2019

A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer.

Clin Genitourin Cancer 2019 Feb 7. Epub 2019 Feb 7.

Cancer Outcomes and Public Policy Effectiveness Research (COPPER) Center, Yale University, New Haven, CT; Department of Medicine, Yale University, New Haven, CT.

Background: Clinical factors and barriers affecting adoption of active surveillance (AS) for low-risk prostate cancer (PCa) remain poorly understood. We performed a national survey of radiation oncologists (RO) and urologists (URO) about the perceptions and recommendations of AS for low-risk PCa.

Materials And Methods: In 2017, we surveyed 915 RO and 940 URO about AS for low-risk PCa in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.008DOI Listing
February 2019
4 Reads

Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.

Clin Genitourin Cancer 2019 Feb 7. Epub 2019 Feb 7.

Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Background: Myalgia and arthralgia immune-related adverse events (irAEs) in patients treated with checkpoint inhibitors (CPIs) present a clinical challenge. We describe the clinical characteristics and treatment of myalgia and arthralgia irAEs in CPI-treated patients with genitourinary (GU) malignancies.

Patients And Methods: Patients with GU malignancies who were treated with CPIs and developed myalgia and arthralgia irAEs that resulted in interruption or discontinuation of CPI therapy were reviewed. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183072
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2019.01.021DOI Listing
February 2019
9 Reads

Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy.

Clin Genitourin Cancer 2019 Jan 26. Epub 2019 Jan 26.

Department of Urology, Emory University School of Medicine, Atlanta, GA; Winship Cancer Institute, Emory Healthcare, Atlanta, GA; Atlanta Veterans Affairs Medical Center, Decatur, GA. Electronic address:

Background: The incidence of node-positive prostate cancer has risen and might be partially explained by evolving use of lymphadenectomy at a population level. We assessed trends of node-positive prostate cancer in context of extent of lymphadenectomy among men treated surgically for prostate cancer.

Patients And Methods: This was a retrospective study using data from a population-based cancer registry to identify men older than 50 years of age diagnosed with prostate cancer from 2010 to 2015 without distant metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.012DOI Listing
January 2019

Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis.

Clin Genitourin Cancer 2019 Jan 30. Epub 2019 Jan 30.

UC San Diego School of Medicine, La Jolla, CA. Electronic address:

Background: We analyzed outcomes of neoadjuvant sunitinib in patients with renal-cell carcinoma (RCC) and inferior vena caval (IVC) tumor and compared outcomes to patients who did not undergo neoadjuvant therapy before surgery.

Patients And Methods: We performed a multicenter retrospective comparison of RCC patients with IVC tumor who underwent neoadjuvant sunitinib before surgery versus those who did not. Response to sunitinib was defined by Response Evaluation Criteria in Solid Tumors (RECIST). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183038
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2019.01.013DOI Listing
January 2019
6 Reads

Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.

Clin Genitourin Cancer 2019 Jan 19. Epub 2019 Jan 19.

Department of Urology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address:

Introduction: Clinical T1 (cT1) bladder cancer is associated with high rates of recurrence, upstaging, and progression. Guidelines recommend that these patients be treated with adjuvant intravesical Bacillus Calmette-Guérin immunotherapy (BCG) or upfront radical cystectomy (RC). We analyzed the National Cancer Database (NCDB) to identify demographic and clinical determinants of guideline-based treatment (GBT) and RC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.007DOI Listing
January 2019
1 Read

Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients.

Clin Genitourin Cancer 2019 Jan 17. Epub 2019 Jan 17.

Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA.

Background: Sarcomatoid renal cell carcinoma (sRCC) constitutes a rare and aggressive subtype of renal cell carcinoma. We aimed to investigate its clinicopathologic characteristics and outcomes at a national level.

Patients And Methods: We accessed the National Cancer Institute's Surveillance, Epidemiology, and End Results database (2010-2015) and extracted data on patients with sRCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.005DOI Listing
January 2019
1 Read

Salvage Surgery After Percutaneous Ablation of Renal Mass in Solitary Kidney in a Patient With Von Hippel-Lindau.

Clin Genitourin Cancer 2019 Jan 26. Epub 2019 Jan 26.

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.011DOI Listing
January 2019

Effects of Variant Histology on the Oncologic Outcomes of Patients With Upper Urinary Tract Carcinoma After Radical Nephroureterectomy: A Propensity Score-Matched Analysis.

Clin Genitourin Cancer 2019 Jan 11. Epub 2019 Jan 11.

Department of Urology, Chonnam National University Medical School, Gwangju, Korea. Electronic address:

Purpose: To determine the prognostic effect of upper tract urothelial carcinoma (UTUC) with variant histology (VH) after radical nephroureterectomy (RNU).

Patients And Methods: The data of 1173 patients who received RNU for UTUC without neoadjuvant chemotherapy in 11 institutions between 2002 and 2016 were retrospectively reviewed. A matched propensity score analysis was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.015DOI Listing
January 2019
2 Reads

Low Expression of ATM Indicates a Poor Prognosis in Clear Cell Renal Cell Carcinoma.

Clin Genitourin Cancer 2019 Jan 10. Epub 2019 Jan 10.

Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan Province, PR China. Electronic address:

Introduction: The study was carried out to examine the expression of ataxia telangiectasia mutant (ATM) of clear cell renal cell carcinoma (ccRCC), and to explore the relationship between the expression of ATM and the clinicopathologic parameters and prognosis of ccRCC.

Materials And Methods: Clinicopathologic data of the patients with ccRCC were collected from January 2011 to August 2015 in Xiangya Hospital, Central South University. The immunohistochemical method was used to detect the expression of ATM in ccRCC and adjacent tissues. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673193001
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2019.01.003DOI Listing
January 2019
7 Reads

Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 Jan 17. Epub 2019 Jan 17.

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Purpose: To investigate the impact of the risk group disagreement between the Memorial Sloan Kettering Cancer Center (MSKCC) and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) models on prognosis.

Patients And Methods: We retrospectively evaluated 176 patients with metastatic renal-cell carcinoma who were treated with tyrosine kinase inhibitors as first-line therapy in 5 hospitals between October 2008 and August 2018. The risk group classification differences between the MSKCC and the IMDC models were evaluated using criteria of agreement (identical risk group in both the MSKCC and IMDC models) and disagreement (not identical risk group in both the MSKCC and IMDC models). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.006DOI Listing
January 2019
1 Read
1.693 Impact Factor

How Are Patients With Prostate Cancer Managing Androgen Deprivation Therapy Side Effects?

Clin Genitourin Cancer 2018 Dec 20. Epub 2018 Dec 20.

University of Calgary, Calgary, AB, Canada; Tom Baker Cancer Centre, Calgary, AB, Canada. Electronic address:

Background: Androgen deprivation therapy (ADT) for prostate cancer has numerous side effects. Clinical guidelines for side effect management exist; however, these are not always integrated into routine practice. What remains undocumented and therefore the objective of this study, is to describe patients' willingness to employ established strategies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183072
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.12.006DOI Listing
December 2018
21 Reads
1.693 Impact Factor

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 Jan 15. Epub 2019 Jan 15.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address:

Renal-cell carcinoma remains one of the elusive cancers that lacks a biomarker. It is the eighth most commonly diagnosed malignancy in the United States, and the incidence has slowly trended upward. In addition to the increase in newly diagnosed cases, the prevalence and overall survival of individuals with kidney cancer also has increased substantially. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.004DOI Listing
January 2019
1 Read

Is Malignant Germ-Cell Tumor Associated With Cowden Syndrome?

Clin Genitourin Cancer 2019 Jan 10. Epub 2019 Jan 10.

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.002DOI Listing
January 2019

Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer.

Clin Genitourin Cancer 2019 Jan 9. Epub 2019 Jan 9.

Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Electronic address:

Background: The aim of this study was to compare survival outcomes in patients with clinically node-positive muscle-invasive bladder cancer receiving induction chemotherapy (IC) followed by surgery and those who underwent upfront radical cystectomy (RC).

Patients And Methods: Outcomes were reviewed in patients with cT2-4N1-3M0 bladder cancer treated with IC followed by surgery or upfront RC between January 1995 and June 2017. Survival outcomes were analyzed using a propensity score matched cohort analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.001DOI Listing
January 2019
2 Reads

Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.

Clin Genitourin Cancer 2019 Apr 21;17(2):145-153.e5. Epub 2018 Dec 21.

Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Background: Prostate cancer with neuroendocrine differentiation (NEPCA) shares similarities in tumor biology with small-cell lung cancer. While immunotherapies were successfully tested in small-cell lung cancer, and programmed death ligand 1 (PD-L1) expression arises as an essential predictive biomarker, the local immune status in NEPCA is still poorly described.

Patients And Methods: Paraffin-embedded tissue samples of 39 patients (7 adenocarcinomas with neuroendocrine differentiation [ACA NED], 20 small-cell neuroendocrine carcinomas, 2 well-differentiated neuroendocrine tumors of NEPCA, and 10 adenocarcinoma liver metastases) were examined retrospectively by immunohistochemistry of chromogranin A (CGA), CD56, synaptophysin (SYN), CD3, and PD-L1. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183058
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.12.007DOI Listing
April 2019
10 Reads

Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials.

Clin Genitourin Cancer 2019 Apr 4;17(2):e339-e344. Epub 2019 Jan 4.

Department of Medical Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.

Although tyrosine kinase inhibitors (TKIs) are widely used in the metastatic setting, they have shown more limited effectiveness in the adjuvant setting. Despite multiple clinical trials, there has been no improvement in overall survival (OS) with the use of these agents as adjuvant therapy, and conflicting data on disease-free survival (DFS). We carried out a meta-analysis of available phase III randomized clinical trials on adjuvant TKIs in clear-cell renal cell carcinoma (RCC). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673193000
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.12.011DOI Listing
April 2019
6 Reads

Outcomes of Prostatectomy versus Radiation Therapy in the Management of Clinically Localized Prostate Cancer Patients Within the PLCO Trial.

Clin Genitourin Cancer 2019 Apr 4;17(2):e329-e338. Epub 2019 Jan 4.

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada. Electronic address:

Background: The objective of the study was to evaluate the outcomes of clinically localized prostate cancer treated with prostatectomy versus radiation therapy within the context of a prospective prostate cancer screening study.

Patients And Methods: Within the PLCO (Prostate, Lung, Colorectal, and Ovary) trial, patients who were diagnosed with clinically localized prostate cancer and subsequently received treatment with prostatectomy or radiation therapy (with or without hormonal treatment) were included. Univariate and multivariate Cox regression analyses were then performed to determine factors affecting overall and prostate cancer-specific survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.010DOI Listing
April 2019
1 Read
1.693 Impact Factor

Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.

Clin Genitourin Cancer 2019 Apr 2;17(2):e323-e328. Epub 2019 Jan 2.

Kantonsspital Graubünden, Chur, Switzerland.

Background: There is evidence linking metformin to improved prostate cancer-related outcomes.

Patients And Methods: Twenty-five men with metastatic castration-resistant prostate cancer and prostate-specific antigen (PSA) progression while receiving treatment with abiraterone from 3 Swiss centers were included in this single-arm phase 2 trial between November 2013 and September 2016. Metformin was added to abiraterone continuously at 1000 mg twice daily in uninterrupted 4-week cycles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.009DOI Listing

Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.

Clin Genitourin Cancer 2019 Feb 4;17(1):38-45. Epub 2018 Oct 4.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada. Electronic address:

Background: Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy improves survival in muscle-invasive urothelial bladder cancer (MIBC). The use of NAC before chemoradiation (CRT) has been limited, as these patients are often elderly, frail, and ineligible for cisplatin. However, the role of NAC in fit, cisplatin-eligible patients who opt for bladder preservation warrants further evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.09.021DOI Listing
February 2019
6 Reads

Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.

Clin Genitourin Cancer 2019 Apr 13;17(2):139-144. Epub 2018 Dec 13.

Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

Background: In the United States, the prostate cancer (PCa) incidence and death rate has been greater in non-Hispanic black (NHB) men than in non-Hispanic white (NHW) men and slightly lower in Hispanic men than in NHW men. We compared the sociodemographic and baseline prognostic factors at the diagnosis of PCa in different races/ethnicities at a large, academic center serving an ethnically diverse population.

Methods: The Montefiore Medical Center Cancer Registry was used to generate a comprehensive list of all patients with PCa diagnosed from 2004 to 2014. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183059
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.12.003DOI Listing
April 2019
18 Reads

Clinicopathologic and Genomic Factors Associated With Oncologic Outcome in Patients With Stage III to IV Chromophobe Renal Cell Carcinoma.

Clin Genitourin Cancer 2019 Apr 8;17(2):e314-e322. Epub 2018 Dec 8.

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Background: Chromophobe renal cell carcinoma (chRCC) is known as an indolent tumor; however, mortality still occurs. We sought to determine the clinicopathologic and genomic factors associated with aggressive chRCC.

Patients And Methods: Two different datasets were used to identify patients with clinical stage III and IV chRCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.002DOI Listing
April 2019
3 Reads

Metronomic Oral Cyclophosphamide in 2 Heavily Pretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report.

Clin Genitourin Cancer 2019 Apr 19;17(2):157-160. Epub 2018 Dec 19.

Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan Branch, Taiwan; School of Medicine, Chang Gung University, Taoyuan City, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.005DOI Listing
April 2019
1 Read

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

Clin Genitourin Cancer 2019 Apr 19;17(2):e383-e386. Epub 2018 Dec 19.

Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183078
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.12.004DOI Listing
April 2019
16 Reads

Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma.

Clin Genitourin Cancer 2019 Apr 7;17(2):e306-e313. Epub 2018 Dec 7.

Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan. Electronic address:

Background: Severe adverse events frequently occur in patients treated with pazopanib, necessitating dose reduction and discontinuation. However, information on the exposure-toxicity relationship is limited.

Patients And Methods: For this retrospective and observational clinical study, we examined 27 patients with renal cell carcinoma treated with pazopanib and enrolled between October 2014 and March 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.12.001DOI Listing
April 2019
2 Reads

Metastatic Urachus Neoplasia: A Case Report and Review of the Current Literature.

Clin Genitourin Cancer 2019 Apr 4;17(2):e377-e382. Epub 2018 Dec 4.

Australian National University Medical School, Canberra, Australia; Department of Oncology, The Canberra Hospital, Canberra, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.017DOI Listing
April 2019
1 Read
1.693 Impact Factor

Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 Apr 22;17(2):e273-e280. Epub 2018 Nov 22.

Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX.

Background: Brain metastases (BM) pose a significant problem in patients with metastatic renal-cell carcinoma (mRCC). Local and systemic therapies including stereotactic radiosurgery (SRS) are rapidly evolving, necessitating reassessments of outcomes for modern patient management.

Patients And Methods: The mRCC patients with BM treated with SRS were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.006DOI Listing
April 2019
6 Reads
1.693 Impact Factor